You are describing a compound that is actually quite important in pharmaceutical research. Let's break down the name and what it means:
**1-(4-Fluorophenyl)-4-hydroxy-3-pyrazolecarboxylic acid ethyl ester**
* **1-(4-Fluorophenyl):** This indicates a phenyl ring (a six-membered carbon ring) with a fluorine atom attached at the 4-position. This phenyl ring is attached to the nitrogen atom at position 1 of the pyrazole ring.
* **4-hydroxy:** This means there is a hydroxyl group (OH) attached to the carbon at position 4 of the pyrazole ring.
* **3-pyrazolecarboxylic acid:** This is the core of the molecule. A pyrazole ring is a five-membered ring containing two nitrogen atoms. The carboxylic acid group (COOH) is attached to the carbon at position 3 of the pyrazole ring.
* **Ethyl ester:** This means the carboxylic acid group has been modified by reacting it with ethanol (ethyl alcohol). The result is an ethyl ester group (COO-CH2-CH3).
**Importance in Research**
This compound and its derivatives are known to exhibit a range of biological activities, particularly:
* **Anti-inflammatory:** It can inhibit the production of inflammatory mediators like prostaglandins and leukotrienes.
* **Anti-tumor:** It has shown potential for inhibiting the growth of various cancer cell lines.
* **Anti-bacterial:** It can inhibit the growth of certain bacteria.
**Why it's important:**
* **Potential drug development:** These activities make this compound a promising candidate for development as a drug for treating inflammatory conditions, cancer, and bacterial infections.
* **Target identification:** Researchers use this compound to study the mechanisms of inflammation, tumor growth, and bacterial resistance. This knowledge can lead to the discovery of new drug targets and the development of more effective treatments.
* **Structure-activity relationship (SAR) studies:** By modifying the structure of this compound, researchers can explore how different chemical groups affect its biological activity. This helps them understand how to optimize its effectiveness and reduce side effects.
**In summary:** 1-(4-Fluorophenyl)-4-hydroxy-3-pyrazolecarboxylic acid ethyl ester is a compound with potential for developing new drugs. Its anti-inflammatory, anti-tumor, and antibacterial properties make it a valuable tool for pharmaceutical research.
ID Source | ID |
---|---|
PubMed CID | 730292 |
CHEMBL ID | 1537402 |
CHEBI ID | 111314 |
SCHEMBL ID | 168643 |
Synonym |
---|
STL305884 |
ethyl 1-(4-fluorophenyl)-4-hydroxy-1h-pyrazole-3-carboxylate |
smr000369384 |
MLS000775810 |
CHEBI:111314 |
F1360-0347 |
636568-08-6 |
1-(4-fluoro-phenyl)-4-hydroxy-1h-pyrazole-3-carboxylic acid ethyl ester |
AB00613527-02 |
AKOS001054912 |
ethyl 1-(4-fluorophenyl)-4-hydroxypyrazole-3-carboxylate |
HMS2713L14 |
SCHEMBL168643 |
ethyl 1-(4-fluorophenyl)-4-hydroxy-pyrazole-3-carboxylate |
WRWOTBYUDNAZFR-UHFFFAOYSA-N |
CHEMBL1537402 |
Q27190931 |
1-(4-fluorophenyl)-4-hydroxy-3-pyrazolecarboxylic acid ethyl ester |
Z56882802 |
sr-01000081940 |
SR-01000081940-1 |
EN300-234938 |
AB90917 |
DTXSID401183667 |
Class | Description |
---|---|
ring assembly | Two or more cyclic systems (single rings or fused systems) which are directly joined to each other by double or single bonds are named ring assemblies when the number of such direct ring junctions is one less than the number of cyclic systems involved. |
pyrazoles | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 19.0115 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 12.5893 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
BRCA1 | Homo sapiens (human) | Potency | 19.9526 | 0.8913 | 7.7225 | 25.1189 | AID624202 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 23.7149 | 0.0041 | 10.8903 | 31.5287 | AID504466; AID504467 |
P53 | Homo sapiens (human) | Potency | 63.0957 | 0.0731 | 9.6858 | 31.6228 | AID504706 |
NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 5.6234 | 0.0126 | 2.4518 | 25.0177 | AID485313 |
ras-related protein Rab-9A | Homo sapiens (human) | Potency | 3.9811 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 89.1251 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
lamin isoform A-delta10 | Homo sapiens (human) | Potency | 0.0050 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 4 (57.14) | 24.3611 |
2020's | 2 (28.57) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.22) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |